ABSTRACT: Herein, we report a method for in vitro selection of multivalent glycopeptides, combining mRNA display with incorporation of unnatural amino acids and “click ” chemistry. We have demonstrated the use of this method to design potential glycopeptide vaccines against HIV. From libraries of ∼1013 glycopeptides containing multiple Man9 glycan(s), we selected variants that bind to HIV broadly neutralizing antibody 2G12 with picomolar to low nanomolar affinity. This is comparable to the strength of the natural 2G12−gp120 interaction, and is the strongest affinity achieved to date with constructs containing 3−5 glycans. These glycopeptides are therefore of great interest in HIV vaccine design. Antibody 2G12, isolated from an HIV positive ...
Enveloped viruses have a great advantage comparedto the non-enveloped viruses due to theirability to...
Two lines of investigation have highlighted the importance of antibodies to the V1/V2 domain of gp12...
Critical to the search for an effective HIV-1 vaccine is the development of immunogens capable of in...
Herein, we report a method for in vitro selection of multivalent glycopeptides, combining mRNA displ...
A class of new glycan-reactive broadly neutralizing antibodies represented by PGT121, 10–1074, and P...
Despite the isolation of several broadly neutralizing anti-HIV antibodies from infected patients, no...
Some conserved glycans on the HIV envelope protein are targets of broadly neutralizing antibodies (b...
The broadly neutralizing antibody PG9 recognizes a unique glycopeptide epitope in the V1V2 domain of...
The glycan shield of human immunodeficiency virus type 1 (HIV-1) gp120 contributes to viral evasion ...
Up to ∼20% of HIV-infected individuals eventually develop broadly neutralizing antibodies (bnAbs), a...
AbstractHuman antibody 2G12 broadly neutralizes human immunodeficiency virus type 1 (HIV-1) isolates...
HIV-1 envelope glycoproteins gp120 and gp41 are presented on the virus surface as a trimer of hetero...
The development of an HIV vaccine has been hampered by the extraordinary mutability and genetic dive...
The N332 high-mannose glycan on the HIV-1 gp120 V3-loop is the target of many bNAbs. About 17% HIV i...
The N332 high-mannose glycan on the HIV-1 gp120 V3-loop is the target of many bNAbs. About 17% HIV i...
Enveloped viruses have a great advantage comparedto the non-enveloped viruses due to theirability to...
Two lines of investigation have highlighted the importance of antibodies to the V1/V2 domain of gp12...
Critical to the search for an effective HIV-1 vaccine is the development of immunogens capable of in...
Herein, we report a method for in vitro selection of multivalent glycopeptides, combining mRNA displ...
A class of new glycan-reactive broadly neutralizing antibodies represented by PGT121, 10–1074, and P...
Despite the isolation of several broadly neutralizing anti-HIV antibodies from infected patients, no...
Some conserved glycans on the HIV envelope protein are targets of broadly neutralizing antibodies (b...
The broadly neutralizing antibody PG9 recognizes a unique glycopeptide epitope in the V1V2 domain of...
The glycan shield of human immunodeficiency virus type 1 (HIV-1) gp120 contributes to viral evasion ...
Up to ∼20% of HIV-infected individuals eventually develop broadly neutralizing antibodies (bnAbs), a...
AbstractHuman antibody 2G12 broadly neutralizes human immunodeficiency virus type 1 (HIV-1) isolates...
HIV-1 envelope glycoproteins gp120 and gp41 are presented on the virus surface as a trimer of hetero...
The development of an HIV vaccine has been hampered by the extraordinary mutability and genetic dive...
The N332 high-mannose glycan on the HIV-1 gp120 V3-loop is the target of many bNAbs. About 17% HIV i...
The N332 high-mannose glycan on the HIV-1 gp120 V3-loop is the target of many bNAbs. About 17% HIV i...
Enveloped viruses have a great advantage comparedto the non-enveloped viruses due to theirability to...
Two lines of investigation have highlighted the importance of antibodies to the V1/V2 domain of gp12...
Critical to the search for an effective HIV-1 vaccine is the development of immunogens capable of in...